Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Breast Cancer

Free Subscription Articles published in Breast Cancer Retrieve available abstracts of 77 articles: HTML format Text format

Single Articles

September 2018
1. OKUMATSU K, Tsujimoto T, Wakaba K, Seki A, et al
   Correction to: Effects of a combined exercise plus diet program on cardiorespiratory fitness of breast cancer patients.
   Breast Cancer. 2018 Sep 17. pii: 10.1007/s12282-018-0902.
   PubMed     Text format     Abstract available
   
   
   
2. KIKAWA Y, Hatachi Y, Rumpold G, Tokiwa M, et al
   Evaluation of health-related quality of life via the Computer-Based Health Evaluation System (CHES) for Japanese metastatic breast cancer patients: a single-center pilot study.
   Breast Cancer. 2018 Sep 7. pii: 10.1007/s12282-018-0905.
   PubMed     Text format     Abstract available
   
   
   
3. TALIMA S, Kaseem H, Kaseem N
   Chemotherapy and targeted therapy for breast cancer patients with hepatitis C virus infection.
   Breast Cancer. 2018 Sep 6. pii: 10.1007/s12282-018-0904.
   PubMed     Text format     Abstract available
   
   
   
4. ABU-KHALAF M, Muralikrishnan S, Hatzis C, Canchi D, et al
   Breast cancer patients with brain metastasis undergoing GKRS.
   Breast Cancer. 2018 Sep 4. pii: 10.1007/s12282-018-0903.
   PubMed     Text format     Abstract available
   
   
   August 2018
5. AYGIN D, Bozdemir H
   Exposure to violence in breast cancer patients: systematic review.
   Breast Cancer. 2018 Aug 22. pii: 10.1007/s12282-018-0900.
   PubMed     Text format     Abstract available
   
   
   
6. NAGASAKA K, Satake H, Ishigaki S, Kawai H, et al
   Histogram analysis of quantitative pharmacokinetic parameters on DCE-MRI: correlations with prognostic factors and molecular subtypes in breast cancer.
   Breast Cancer. 2018 Aug 1. pii: 10.1007/s12282-018-0899.
   PubMed     Text format     Abstract available
   
   
   July 2018
7. ALTUNDAG K
   Younger breast cancer patients under the age of 35 might have a better disease-free survival if they received ovarian function suppression more than 3 years.
   Breast Cancer. 2018 Jul 28. pii: 10.1007/s12282-018-0897.
   PubMed     Text format    
   
   
   
8. NAKATSUKASA K, Koyama H, Ouchi Y, Ono H, et al
   Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
   Breast Cancer. 2018 Jul 27. pii: 10.1007/s12282-018-0896.
   PubMed     Text format     Abstract available
   
   
   
9. AFTAB A, Shahzad S, Hussain HMJ, Khan R, et al
   CDKN2A/P16INK4A variants association with breast cancer and their in-silico analysis.
   Breast Cancer. 2018 Jul 23. pii: 10.1007/s12282-018-0894.
   PubMed     Text format     Abstract available
   
   
   
10. NOGUCHI E, Tamura K, Hattori M, Horiguchi J, et al
    Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study.
    Breast Cancer. 2018 Jul 23. pii: 10.1007/s12282-018-0887.
    PubMed     Text format     Abstract available
    
    
    
11. LIU C, Liu Y, Chen L, Zhang M, et al
    Quantitative proteome and lysine succinylome analyses provide insights into metabolic regulation in breast cancer.
    Breast Cancer. 2018 Jul 18. pii: 10.1007/s12282-018-0893.
    PubMed     Text format     Abstract available
    
    
    
12. OKUMATSU K, Tsujimoto T, Wakaba K, Seki A, et al
    Effects of a combined exercise plus diet program on cardiorespiratory fitness of breast cancer patients.
    Breast Cancer. 2018 Jul 10. pii: 10.1007/s12282-018-0889.
    PubMed     Text format     Abstract available
    
    
    
13. MA D, Chen C, Wu J, Wang H, et al
    Up-regulated lncRNA AFAP1-AS1 indicates a poor prognosis and promotes carcinogenesis of breast cancer.
    Breast Cancer. 2018 Jul 5. pii: 10.1007/s12282-018-0891.
    PubMed     Text format     Abstract available
    
    
    
14. TOKUNAGA E, Fujita A, Takizawa K, Baba K, et al
    CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Breast Cancer. 2018 Jul 3. pii: 10.1007/s12282-018-0888.
    PubMed     Text format     Abstract available
    
    
    June 2018
15. PENG X, Yan B, Shen Y
    MiR-1301-3p inhibits human breast cancer cell proliferation by regulating cell cycle progression and apoptosis through directly targeting ICT1.
    Breast Cancer. 2018 Jun 27. pii: 10.1007/s12282-018-0881.
    PubMed     Text format     Abstract available
    
    
    
16. LIU L, Yin B, Yi Z, Liu X, et al
    Breast cancer stem cells characterized by CD70 expression preferentially metastasize to the lungs.
    Breast Cancer. 2018 Jun 14. pii: 10.1007/s12282-018-0880.
    PubMed     Text format     Abstract available
    
    
    
17. TAKABATAKE D, Kajiwara Y, Ohtani S, Itano Y, et al
    The efficacy and feasibility of dose-dense sequential chemotherapy for Japanese patients with breast cancer.
    Breast Cancer. 2018 Jun 11. pii: 10.1007/s12282-018-0877.
    PubMed     Text format     Abstract available
    
    
    
18. TOYAMA T, Yoshimura A, Hayashi T, Kobayashi N, et al
    A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer.
    Breast Cancer. 2018 Jun 8. pii: 10.1007/s12282-018-0879.
    PubMed     Text format     Abstract available
    
    
    May 2018
19. LOUHICHI T, Ziadi S, Saad H, Dhiab MB, et al
    Clinicopathological significance of cancer stem cell markers CD44 and ALDH1 expression in breast cancer.
    Breast Cancer. 2018 May 29. pii: 10.1007/s12282-018-0875.
    PubMed     Text format     Abstract available
    
    
    
20. SAJI S
    The long and winding road for overcoming resistance to hormone therapy in breast cancer.
    Breast Cancer. 2018 May 28. pii: 10.1007/s12282-018-0876.
    PubMed     Text format    
    
    
    
21. GAO L, Li SC
    Cost-effectiveness analysis of lipegfilgrastim as primary prophylaxis in women with breast cancer in Australia: a modelled economic evaluation.
    Breast Cancer. 2018 May 25. pii: 10.1007/s12282-018-0872.
    PubMed     Text format     Abstract available
    
    
    
22. WEN L, Liu L, Wen L, Yu T, et al
    Artesunate promotes G2/M cell cycle arrest in MCF7 breast cancer cells through ATM activation.
    Breast Cancer. 2018 May 24. pii: 10.1007/s12282-018-0873.
    PubMed     Text format     Abstract available
    
    
    
23. OSTAPCHUK YO, Perfilyeva YV, Kustova EA, Urazalieva NT, et al
    Functional heterogeneity of circulating T regulatory cell subsets in breast cancer patients.
    Breast Cancer. 2018 May 24. pii: 10.1007/s12282-018-0874.
    PubMed     Text format     Abstract available
    
    
    
24. LEE SB, Sohn G, Kim J, Chung IY, et al
    Survival analysis according to period and analysis of the factors influencing changes in survival in patients with recurrent breast cancer: a large-scale, single-center study.
    Breast Cancer. 2018 May 21. pii: 10.1007/s12282-018-0869.
    PubMed     Text format     Abstract available
    
    
    
25. TAKADA M, Takeuchi M, Suzuki E, Sato F, et al
    Real-time navigation system for sentinel lymph node biopsy in breast cancer patients using projection mapping with indocyanine green fluorescence.
    Breast Cancer. 2018 May 9. pii: 10.1007/s12282-018-0868.
    PubMed     Text format     Abstract available
    
    
    
26. JAMAN MS, Sayeed MA
    Ellagic acid, sulforaphane, and ursolic acid in the prevention and therapy of breast cancer: current evidence and future perspectives.
    Breast Cancer. 2018 May 3. pii: 10.1007/s12282-018-0866.
    PubMed     Text format     Abstract available
    
    
    
27. GLOWACKA-MROTEK I, Sowa M, Nowikiewicz T, Siedlecki Z, et al
    Foot posture in female patients 5 years after breast-conserving surgery: a case-control study.
    Breast Cancer. 2018;25:325-333.
    PubMed     Text format     Abstract available
    
    
    April 2018
28. KWAPISZ D
    Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
    Breast Cancer. 2018 Apr 26. pii: 10.1007/s12282-018-0864.
    PubMed     Text format     Abstract available
    
    
    
29. SAKAI H, Tsurutani J, Iwasa T, Komoike Y, et al
    HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer.
    Breast Cancer. 2018 Apr 26. pii: 10.1007/s12282-018-0861.
    PubMed     Text format     Abstract available
    
    
    
30. WANG NN, Yang ZJ, Wang X, Chen LX, et al
    A mathematical prediction model incorporating molecular subtype for risk of non-sentinel lymph node metastasis in sentinel lymph node-positive breast cancer patients: a retrospective analysis and nomogram development.
    Breast Cancer. 2018 Apr 25. pii: 10.1007/s12282-018-0863.
    PubMed     Text format     Abstract available
    
    
    
31. AOYAGI T, Takabe K, Tamanuki T, Matsubara H, et al
    Pseudocirrhosis after chemotherapy in breast cancer, case reports.
    Breast Cancer. 2018 Apr 25. pii: 10.1007/s12282-018-0865.
    PubMed     Text format     Abstract available
    
    
    
32. OHASHI R, Nagao M, Nakamura I, Okamoto T, et al
    Improvement in diagnostic performance of breast cancer: comparison between conventional digital mammography alone and conventional mammography plus digital breast tomosynthesis.
    Breast Cancer. 2018 Apr 12. pii: 10.1007/s12282-018-0859.
    PubMed     Text format     Abstract available
    
    
    
33. NAZARI SS, Mukherjee P
    An overview of mammographic density and its association with breast cancer.
    Breast Cancer. 2018 Apr 12. pii: 10.1007/s12282-018-0857.
    PubMed     Text format     Abstract available
    
    
    
34. LI Q, Gao H, Zhou S, Liao Y, et al
    LncRNA PlncRNA-1 overexpression inhibits the growth of breast cancer by upregulating TGF-beta1 and downregulating PHGDH.
    Breast Cancer. 2018 Apr 6. pii: 10.1007/s12282-018-0858.
    PubMed     Text format     Abstract available
    
    
    
35. IWASE M, Sawaki M, Hattori M, Yoshimura A, et al
    Assessing residual cancer cells using MRI and US after preoperative chemotherapy in primary breast cancer to omit surgery.
    Breast Cancer. 2018 Apr 4. pii: 10.1007/s12282-018-0856.
    PubMed     Text format     Abstract available
    
    
    March 2018
36. SASADA S, Shien T, Iwata H
    Current status of postmastectomy radiation therapy in T1-2 breast cancer with limited positive lymph nodes in Japan: Japan Clinical Oncology Group Survey.
    Breast Cancer. 2018 Mar 23. pii: 10.1007/s12282-018-0855.
    PubMed     Text format    
    
    
    
37. WAKABAYASHI H, Hamaguchi T, Nagao N, Kato S, et al
    Interleukin-6 receptor inhibitor suppresses bone metastases in a breast cancer cell line.
    Breast Cancer. 2018 Mar 19. pii: 10.1007/s12282-018-0853.
    PubMed     Text format     Abstract available
    
    
    
38. ZHANG JM, Wei K, Jiang M
    OCT4 but not SOX2 expression correlates with worse prognosis in surgical patients with triple-negative breast cancer.
    Breast Cancer. 2018 Mar 13. pii: 10.1007/s12282-018-0844.
    PubMed     Text format     Abstract available
    
    
    
39. YOSHIMURA A, Okumura S, Sawaki M, Hattori M, et al
    Feasibility study of contralateral risk-reducing mastectomy with breast reconstruction for breast cancer patients with BRCA mutations in Japan.
    Breast Cancer. 2018 Mar 8. pii: 10.1007/s12282-018-0850.
    PubMed     Text format     Abstract available
    
    
    
40. KA WH, Cho SK, Chun BN, Byun SY, et al
    The ubiquitin ligase COP1 regulates cell cycle and apoptosis by affecting p53 function in human breast cancer cell lines.
    Breast Cancer. 2018 Mar 7. pii: 10.1007/s12282-018-0849.
    PubMed     Text format     Abstract available
    
    
    February 2018
41. RAMOS-ESQUIVEL A, Hernandez-Steller H, Savard MF, Landaverde DU, et al
    Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
    Breast Cancer. 2018 Feb 22. pii: 10.1007/s12282-018-0848.
    PubMed     Text format     Abstract available
    
    
    
42. NOGUCHI S, Ellis MJ, Robertson JFR, Thirlwell J, et al
    Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON).
    Breast Cancer. 2018 Feb 15. pii: 10.1007/s12282-018-0838.
    PubMed     Text format     Abstract available
    
    
    
43. MASUDA N, Toi M, Yamamoto N, Iwata H, et al
    Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicent
    Breast Cancer. 2018 Feb 14. pii: 10.1007/s12282-018-0839.
    PubMed     Text format     Abstract available
    
    
    
44. CHEN W, Lv X, Xu X, Gao X, et al
    Meta-analysis for psychological impact of breast reconstruction in patients with breast cancer.
    Breast Cancer. 2018 Feb 13. pii: 10.1007/s12282-018-0846.
    PubMed     Text format     Abstract available
    
    
    
45. OHTANI S, Nakayama T, Yoshinami T, Watanabe KI, et al
    Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).
    Breast Cancer. 2018 Feb 12. pii: 10.1007/s12282-018-0843.
    PubMed     Text format     Abstract available
    
    
    
46. SURYAVANSHI M, Mehta A, Jaipuria J, Kumar D, et al
    Clinical utility of RT-PCR in assessing HER 2 gene expression versus traditional IHC and FISH in breast cancer patients.
    Breast Cancer. 2018 Feb 9. pii: 10.1007/s12282-018-0840.
    PubMed     Text format     Abstract available
    
    
    
47. ZOU L, Liu FH, Shen PP, Hu Y, et al
    The incidence and risk factors of related lymphedema for breast cancer survivors post-operation: a 2-year follow-up prospective cohort study.
    Breast Cancer. 2018 Feb 3. pii: 10.1007/s12282-018-0830.
    PubMed     Text format     Abstract available
    
    
    
48. IWATA H
    Clinical development of CDK4/6 inhibitor for breast cancer.
    Breast Cancer. 2018 Feb 1. pii: 10.1007/s12282-017-0827.
    PubMed     Text format     Abstract available
    
    
    January 2018
49. WANG Y, Wang J, Long F, Wang N, et al
    Correlation of FANCM expression with clinical factors in luminal B breast cancer.
    Breast Cancer. 2018 Jan 31. pii: 10.1007/s12282-018-0841.
    PubMed     Text format     Abstract available
    
    
    
50. KHAN RT, Siddique A, Shahid N, Khokher S, et al
    Breast cancer risk associated with genes encoding DNA repair MRN complex: a study from Punjab, Pakistan.
    Breast Cancer. 2018 Jan 24. pii: 10.1007/s12282-018-0837.
    PubMed     Text format     Abstract available
    
    
    
51. NGUYEN-THU H, Hanaoka H, Nakajima T, Yamaguchi A, et al
    Early prediction of triple negative breast cancer response to cisplatin treatment using diffusion-weighted MRI and (18)F-FDG-PET.
    Breast Cancer. 2018 Jan 22. pii: 10.1007/s12282-018-0834.
    PubMed     Text format     Abstract available
    
    
    
52. OZAKI Y, Tanabe Y, Tamura N, Ogura T, et al
    Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
    Breast Cancer. 2018 Jan 22. pii: 10.1007/s12282-018-0836.
    PubMed     Text format     Abstract available
    
    
    
53. YANG ZJ, Yu Y, Chi JR, Guan M, et al
    The combined pN stage and breast cancer subtypes in breast cancer: a better discriminator of outcome can be used to refine the 8th AJCC staging manual.
    Breast Cancer. 2018 Jan 20. pii: 10.1007/s12282-018-0833.
    PubMed     Text format     Abstract available
    
    
    
54. HABYARIMANA T, Attaleb M, Mazarati JB, Bakri Y, et al
    Detection of human papillomavirus DNA in tumors from Rwandese breast cancer patients.
    Breast Cancer. 2018 Jan 19. pii: 10.1007/s12282-018-0831.
    PubMed     Text format     Abstract available
    
    
    
55. INARI H, Shimizu S, Suganuma N, Yoshida T, et al
    Correction to: A comparison of clinicopathological characteristics and long-term survival outcomes between symptomatic and screen-detected breast cancer in Japanese women.
    Breast Cancer. 2018 Jan 10. pii: 10.1007/s12282-018-0832.
    PubMed     Text format     Abstract available
    
    
    
56. PIVOT X, Im SA, Guo M, Marme F, et al
    Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.
    Breast Cancer. 2018 Jan 4. pii: 10.1007/s12282-017-0826.
    PubMed     Text format     Abstract available
    
    
    December 2017
57. PIERRISNARD C, Baciuchka M, Mancini J, Rathelot P, et al
    Body image and psychological distress in women with breast cancer: a French online survey on patients' perceptions and expectations.
    Breast Cancer. 2017 Dec 29. pii: 10.1007/s12282-017-0828.
    PubMed     Text format     Abstract available
    
    
    
58. ATTALLAH AM, El-Far M, Abdelrazek MA, Omran MM, et al
    HCV nonstructural protein 4 is associated with aggressiveness features of breast cancer.
    Breast Cancer. 2017 Dec 28. pii: 10.1007/s12282-017-0829.
    PubMed     Text format     Abstract available
    
    
    
59. SHIMOI T, Yoshida M, Kitamura Y, Yoshino T, et al
    TERT promoter hotspot mutations in breast cancer.
    Breast Cancer. 2017 Dec 8. pii: 10.1007/s12282-017-0825.
    PubMed     Text format     Abstract available
    
    
    
60. TSUDA B, Miyamoto A, Yokoyama K, Ogiya R, et al
    B-cell populations are expanded in breast cancer patients compared with healthy controls.
    Breast Cancer. 2017 Dec 4. pii: 10.1007/s12282-017-0824.
    PubMed     Text format     Abstract available
    
    
    
61. DORFEL S, Steffens CC, Meyer D, Tesch H, et al
    Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study.
    Breast Cancer. 2017 Dec 4. pii: 10.1007/s12282-017-0823.
    PubMed     Text format     Abstract available
    
    
    
62. HE J, Chen Y, Cai L, Li Z, et al
    UBAP2L silencing inhibits cell proliferation and G2/M phase transition in breast cancer.
    Breast Cancer. 2017 Dec 1. pii: 10.1007/s12282-017-0820.
    PubMed     Text format     Abstract available
    
    
    November 2017
63. INOUE H, Horii R, Ito Y, Iwase T, et al
    Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer.
    Breast Cancer. 2017 Nov 28. pii: 10.1007/s12282-017-0822.
    PubMed     Text format     Abstract available
    
    
    
64. ZHANG ZL, Jiang QC, Wang SR
    Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
    Breast Cancer. 2017 Nov 27. pii: 10.1007/s12282-017-0821.
    PubMed     Text format     Abstract available
    
    
    
65. ZHAO Q, Song W, He DY, Li Y, et al
    Identification of key gene modules and pathways of human breast cancer by co-expression analysis.
    Breast Cancer. 2017 Nov 23. pii: 10.1007/s12282-017-0817.
    PubMed     Text format     Abstract available
    
    
    
66. HATTORI M, Ishiguro H, Masuda N, Yoshimura A, et al
    Correction to: Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.
    Breast Cancer. 2017 Nov 20. doi: 10.1007/s12282-017-0815.
    PubMed     Text format     Abstract available
    
    
    
67. KASSEM L, Shohdy KS, Lasheen S, Abdel-Rahman O, et al
    Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
    Breast Cancer. 2017 Nov 16. doi: 10.1007/s12282-017-0818.
    PubMed     Text format     Abstract available
    
    
    
68. WANG R, Li J, Zhao Y, Li Y, et al
    Investigating the therapeutic potential and mechanism of curcumin in breast cancer based on RNA sequencing and bioinformatics analysis.
    Breast Cancer. 2017 Nov 14. doi: 10.1007/s12282-017-0816.
    PubMed     Text format     Abstract available
    
    
    
69. ADHAMI M, Haghdoost AA, Sadeghi B, Malekpour Afshar R, et al
    Candidate miRNAs in human breast cancer biomarkers: a systematic review.
    Breast Cancer. 2017 Nov 3. doi: 10.1007/s12282-017-0814.
    PubMed     Text format     Abstract available
    
    
    
70. SHIGEMATSU H, Ozaki S, Yasui D, Zaitsu J, et al
    Comparison of CK-IHC assay on serial frozen sections, the OSNA assay, and in combination for intraoperative evaluation of SLN metastases in breast cancer.
    Breast Cancer. 2017 Nov 1. doi: 10.1007/s12282-017-0811.
    PubMed     Text format     Abstract available
    
    
    
71. HARAO M, Ando J, Kamata H, Hoshi N, et al
    Peritoneal cancer arising after total abdominal hysterectomy and bilateral salpingo-oophorectomy for cervical cancer in a patient with right breast cancer and germline mutation of BRCA1 gene: a case report and literature review.
    Breast Cancer. 2017 Nov 1. doi: 10.1007/s12282-017-0813.
    PubMed     Text format     Abstract available
    
    
    October 2017
72. ARAKI K, Miyoshi Y
    Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
    Breast Cancer. 2017 Oct 31. doi: 10.1007/s12282-017-0812.
    PubMed     Text format     Abstract available
    
    
    
73. KHPAL M, Miller JRC, Petrovic Z, Hassanally D, et al
    Local anesthetic delivery via surgical drain provides improved pain control versus direct skin infiltration following axillary node dissection for breast cancer.
    Breast Cancer. 2017 Oct 26. doi: 10.1007/s12282-017-0810.
    PubMed     Text format     Abstract available
    
    
    
74. REGEV-AVRAHAM Z, Baron-Epel O, Hammond SK, Keinan-Boker L, et al
    Passive smoking, NAT2 polymorphism, and breast cancer risk in Israeli Arab women: a case-control study.
    Breast Cancer. 2017 Oct 26. doi: 10.1007/s12282-017-0809.
    PubMed     Text format     Abstract available
    
    
    
75. OGITA M, Nagura N, Kawamori J, In R, et al
    Risk factors for complications among breast cancer patients treated with post-mastectomy radiotherapy and immediate tissue-expander/permanent implant reconstruction: a retrospective cohort study.
    Breast Cancer. 2017 Oct 19. doi: 10.1007/s12282-017-0808.
    PubMed     Text format     Abstract available
    
    
    
76. TOYODA Y, Tabuchi T, Nakayama T, Hojo S, et al
    Trends in the clinical stage distribution of breast cancer in Osaka, Japan.
    Breast Cancer. 2017 Oct 12. doi: 10.1007/s12282-017-0807.
    PubMed     Text format     Abstract available
    
    
    September 2017
77. ALTUNDAG K
    Questions about lower inner zone tumors in early-stage breast cancer.
    Breast Cancer. 2017 Sep 14. doi: 10.1007/s12282-017-0801.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: